These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
585 related articles for article (PubMed ID: 31299995)
1. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995 [TBL] [Abstract][Full Text] [Related]
2. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8 Li Y; Shi X; Mao B; Wang L; Wu L; Li J; Jiao S Lung Cancer; 2022 Apr; 166():161-169. PubMed ID: 35287068 [TBL] [Abstract][Full Text] [Related]
3. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy. Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799 [TBL] [Abstract][Full Text] [Related]
4. Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images. Ono A; Terada Y; Kawata T; Serizawa M; Isaka M; Kawabata T; Imai T; Mori K; Muramatsu K; Hayashi I; Kenmotsu H; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Akiyama Y; Sugino T; Ohde Y; Yamaguchi K; Takahashi T Cancer Med; 2020 Jul; 9(13):4864-4875. PubMed ID: 32400056 [TBL] [Abstract][Full Text] [Related]
5. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of PD-L1 expression in combination with CD8 Yang H; Shi J; Lin D; Li X; Zhao C; Wang Q; Zhang L; Jiang T; Zhao S; Liu X; Jia Y; Zhang Y; Cai W; Zhou C Cancer Med; 2018 Jan; 7(1):32-45. PubMed ID: 29168339 [TBL] [Abstract][Full Text] [Related]
7. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes. Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519 [TBL] [Abstract][Full Text] [Related]
9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of PD-L1 expression and CD8 Cheng X; Wang L; Zhang Z J Thorac Dis; 2022 Jun; 14(6):2224-2234. PubMed ID: 35813758 [TBL] [Abstract][Full Text] [Related]
11. Aligning digital CD8 Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764 [TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas. Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984 [TBL] [Abstract][Full Text] [Related]
14. Dynamic changes in PD-L1 expression and CD8 Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259 [TBL] [Abstract][Full Text] [Related]
15. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression. Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J Front Immunol; 2021; 12():798424. PubMed ID: 35145511 [TBL] [Abstract][Full Text] [Related]
16. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma. Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782 [TBL] [Abstract][Full Text] [Related]
17. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552 [TBL] [Abstract][Full Text] [Related]
18. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125 [TBL] [Abstract][Full Text] [Related]
19. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer. Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443 [TBL] [Abstract][Full Text] [Related]
20. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. Ricciuti B; Wang X; Alessi JV; Rizvi H; Mahadevan NR; Li YY; Polio A; Lindsay J; Umeton R; Sinha R; Vokes NI; Recondo G; Lamberti G; Lawrence M; Vaz VR; Leonardi GC; Plodkowski AJ; Gupta H; Cherniack AD; Tolstorukov MY; Sharma B; Felt KD; Gainor JF; Ravi A; Getz G; Schalper KA; Henick B; Forde P; Anagnostou V; Jänne PA; Van Allen EM; Nishino M; Sholl LM; Christiani DC; Lin X; Rodig SJ; Hellmann MD; Awad MM JAMA Oncol; 2022 Aug; 8(8):1160-1168. PubMed ID: 35708671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]